Clinical trials: Bladder
Various Advanced Cancer
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
- Trial name
- NCT02387996
- Testing
- Nivolumab
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Transitional Cell Carcinoma of Bladder
Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma
Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG (number of participants with AEs, discontinuations due to AEs) Recurrence after treatment with BC-819/PEI and BCG Approximately 38…
- Trial name
- NCT01878188
- Testing
- BC-819/PEI, BCG Vaccine
- Where
- 7 sites in Israel
- Volunteers
- 38 people
- Sponsor
- Anchiano Therapeutics Israel Ltd.
Overactive Bladder
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms
To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical…
- Trial name
- NCT04999657
- Testing
- Non-invasive low-frequency tibial nerve stimulator (TNS-01)
- Where
- 7 sites in China
- Volunteers
- 109 people
- Sponsor
- Medtecx Co Ltd.
Bladder Function
A Pilot Trial in a Sleep Laboratory Setting to Observe Night Time Bladder Function of Subjects With Overactive Bladder (OAB)
This is an observational, pilot, non-treatment study to evaluate and develop clinical variables for distinguishing female OAB subjects that have detrusor overactivity positive (DO+) nocturia from female OAB subjects that have…
- Trial name
- NCT01099345
- Testing
- cystometry (CMG), polysomnography (PSG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Astellas Pharma Inc
Urothelial Bladder Cancer, Triple-negative Breast Cancer
Study of Tremelimumab in Patients With Advanced Solid Tumors
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
- Conditions
- Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02527434
- Testing
- Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy
- Where
- 14 sites in United States, Belgium and 3 more
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Adenocarcinoma (NOS), Anal Cancer
DESTINY-PANTUMOUR04
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease…
- Conditions
- Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- DP-04 (NCT07124000)
- Testing
- Trastuzumab deruxtecan
- Where
- 18 sites in United States
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Urinary Retention, Neurogenic Bladder
Consumer Evaluation of an Investigational Intermittent Catheter
This clinical study is designed to evaluate the initial safety and performance of an investigational intermittent urinary catheter in people who use intermittent catheterization.
- Trial name
- NCT07714694
- Testing
- An intermittent urethral urinary catheter with a tip, tube and drainage eyelets
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hollister Incorporated
Bladder Cancer
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation
- Trial name
- RIVERS (NCT07038928)
- Where
- 20 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Interstitial Cystitis
Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis
To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.
- Trial name
- NCT00295854
- Testing
- MN-001 BID, MN-001
- Where
- 28 sites in United States
- Volunteers
- 296 people
- Sponsor
- MediciNova
Advanced Solid Tumor, Unresectable Solid Tumor
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma
- Trial name
- GUARDIAN-101 (NCT06778863)
- Testing
- CLSP-1025
- Where
- 21 sites in United States
- Volunteers
- 90 people
- Sponsor
- Clasp Therapeutics, Inc.
Superficial Bladder Cancer
Therapeutic Instillation of Mistletoe
The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence.
- Trial name
- TIM (NCT02106572)
- Testing
- abnobaVISCUM 900, Mitomycin C
- Where
- 5 sites in Egypt, Germany
- Volunteers
- 174 people
- Sponsor
- Abnoba Gmbh
Interstitial Cystitis and Bladder Pain Syndrome
Real-world Evidence Study on Cystistat
This study will be conducted with the aim of ensuring the continued acceptability of the benefit-risk ratio and confirming the safety and performance of the device throughout its expected lifetime.
- Trial name
- IC/BPS (NCT05544695)
- Testing
- intravesical sodium hyaluronate (Cystistat®)
- Where
- Austria
- Volunteers
- 74 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Bladder Cancer
Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT01373398
- Testing
- EO9(Apaziquone)
- Where
- 2 sites in South Korea
- Volunteers
- 11 people
- Sponsor
- Handok Inc.
Urinary Incontinence, Overactive Bladder With Urinary Incontinence
BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence
This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
- Trial name
- APOLLO (NCT03320850)
- Testing
- OnabotulinumtoxinA and Hydrogel admixture
- Where
- 63 sites in United States, Canada
- Volunteers
- 383 people
- Sponsor
- Allergan
Bladder Infections and Inflammations
Chronic Indwelling Foley and Catheter Associated Trauma (CIF-CAT) Study
To determine whether an indwelling low profile Kohli Atraumatic Catheter causes less macro-morphologic inflammation and edema to the bladder mucosa than a traditional indwelling Foley catheter as assess by computerized image…
- Trial name
- NCT03790826
- Testing
- cystoscopy
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nellie Medical, LLC
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a chronic and debilitating urological complex of disorders characterized by symptoms of bladder pain or discomfort, mostly upon bladder filling, and often accompanied by…
- Trial name
- IC/BPS POC (NCT05141006)
- Testing
- BOTOX
- Where
- 43 sites in United States, Canada
- Volunteers
- 83 people
- Sponsor
- AbbVie
Overactive Bladder, Urge Incontinence
eCoin for OAB Feasibility Follow-on Study
This trial is a prospective, multicenter, single-arm follow-on study will evaluate the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects with urgency urinary incontinence (UUI) as defined by the American…
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03655054
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 7 sites in United States, New Zealand
- Volunteers
- 23 people
- Sponsor
- Valencia Technologies Corporation
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Urinary Bladder, Overactive
Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
This single-dose study will investigate how well solifenacin suspension is taken up, how long it stays in the body and how well it will be tolerated in children and adolescents aged 5-17 years with symptoms of overactive bladder.
- Trial name
- NCT01262391
- Testing
- Solifenacin succinate suspension 2.5 mg, Solifenacin succinate suspension 5 mg, Solifenacin succinate suspension 10 mg
- Where
- 8 sites in Belgium, Denmark and 2 more
- Volunteers
- 42 people
- Sponsor
- Astellas Pharma Inc
Colorectal Cancer, Gastro Esophageal Junctional Cancer
IKS04 Regimen in Advanced Solid Tumors That Express CA242
This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify a recommended phase 2 dose (RP2D) or recommended dose for further…
- Conditions
- Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma
- Trial name
- NCT07738939
- Testing
- IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Iksuda Therapeutics Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.